دورية أكاديمية
أعرض في EDS

LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial.

التفاصيل البيبلوغرافية
العنوان: LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial.
المؤلفون: Steinberg WM; From the *Department of Medicine, George Washington University Medical Center, Rockville, MD; †Department of Internal Medicine/Diabetology, Diabeteszentrum Bad Lauterberg, Bad Lauterberg im Harz, Germany; ‡Department of Medicine, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada; §Thyroid Unit and Department of Medicine, Massachusetts General Hospital Harvard Medical School, Boston, MA; ║Park Nicollet Institute for Research and Education, International Diabetes Center, Minneapolis, MN; ¶Department of Medicine, Friedrich Alexander University of Erlangen, Erlangen, Germany; #Novo Nordisk, A/S, Bagsvaerd, Denmark; **Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern, Dallas, TX; and ††Division of Endocrinology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC., Nauck MA, Zinman B, Daniels GH, Bergenstal RM, Mann JF, Steen Ravn L, Moses AC, Stockner M, Baeres FM, Marso SP, Buse JB
مؤلفون مشاركون: LEADER Trial investigators
المصدر: Pancreas [Pancreas] 2014 Nov; Vol. 43 (8), pp. 1223-31.
نوع المنشور: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 8608542 Publication Model: Print Cited Medium: Internet ISSN: 1536-4828 (Electronic) Linking ISSN: 08853177 NLM ISO Abbreviation: Pancreas Subsets: MEDLINE
أسماء مطبوعة: Publication: Hagerstown, MD : Lippincott Williams & Wilkins
Original Publication: [New York, N.Y.] : Raven Press, [c1986-
مواضيع طبية MeSH: Amylases/*blood , Diabetes Mellitus, Type 2/*enzymology , Lipase/*blood, Acute Disease ; Aged ; Biomarkers ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/drug therapy ; Double-Blind Method ; Fasting/blood ; Female ; Glucagon-Like Peptide 1/adverse effects ; Glucagon-Like Peptide 1/analogs & derivatives ; Glucagon-Like Peptide 1/pharmacology ; Glucagon-Like Peptide 1/therapeutic use ; Humans ; Hypoglycemic Agents/adverse effects ; Hypoglycemic Agents/pharmacology ; Hypoglycemic Agents/therapeutic use ; Kidney/physiopathology ; Liraglutide ; Male ; Middle Aged ; Pancreatitis/chemically induced ; Pancreatitis/etiology ; Pancreatitis/prevention & control
مستخلص: Objectives: This report from the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial describes baseline lipase and amylase activity in type 2 diabetic subjects without acute pancreatitis symptoms before randomization to the glucagonlike peptide analog liraglutide or placebo.
Methods: The LEADER is an international randomized placebo-controlled trial evaluating the cardiovascular safety of liraglutide in 9340 type 2 diabetic patients at high cardiovascular risk. Fasting lipase and amylase activity was assessed at baseline, before receiving liraglutide or placebo, using a commercial assay (Roche) with upper limit of normal values of 63 U/L for lipase and 100 U/L for amylase.
Results: Either or both enzymes were above the upper limit of normal in 22.7% of subjects; 16.6% (n = 1540) had an elevated lipase level (including 1.2% >3-fold elevated), and 11.8% (n = 1094) had an elevated amylase level (including 0.2% >3-fold elevated). In multivariable regression models, severely reduced kidney function was associated with the largest effect on increasing activity of both. However, even among subjects with normal kidney function, 12.2% and 7.7% had elevated lipase and amylase levels.
Conclusions: In this large study of type 2 diabetic patients, nearly 25% had elevated lipase or amylase levels without symptoms of acute pancreatitis. The clinician must take these data into account when evaluating abdominal symptoms in type 2 diabetic patients.
References: Diabetes. 2013 Jul;62(7):2595-604. (PMID: 23524641)
Diabetes Obes Metab. 2010 Sep;12(9):766-71. (PMID: 20649628)
Ann Pharmacother. 2011 Apr;45(4):e22. (PMID: 21487080)
J Nutr. 1994 Aug;124(8):1166-71. (PMID: 8064366)
J Clin Chem Clin Biochem. 1988 Oct;26(10):611-5. (PMID: 2466098)
Diabetes Res Clin Pract. 2012 Nov;98(2):271-84. (PMID: 23010561)
Clin Chem. 1988 Aug;34(8):1552-5. (PMID: 3261213)
Curr Med Res Opin. 2009 Apr;25(4):1019-27. (PMID: 19278373)
Am J Gastroenterol. 1977 Dec;68(6):572-7. (PMID: 612214)
J Clin Endocrinol Metab. 2010 Dec;95(12):5449-53. (PMID: 20843949)
J Emerg Med. 2010 May;38(4):463-6. (PMID: 18993019)
Diabetes Care. 2006 Feb;29(2):471. (PMID: 16443920)
JAMA Intern Med. 2013 Apr 8;173(7):534-9. (PMID: 23440284)
Gut. 2013 Jan;62(1):102-11. (PMID: 23100216)
Gastroenterology. 1990 Dec;99(6):1763-71. (PMID: 2227289)
Diabetes Obes Metab. 2011 Jun;13(6):559-66. (PMID: 21320263)
Gut. 1975 Dec;16(12):1006-9. (PMID: 1218813)
Gastroenterology. 2013 Jun;144(6):1252-61. (PMID: 23622135)
Diabetes Care. 2010 Nov;33(11):2349-54. (PMID: 20682680)
Am J Obstet Gynecol. 1957 Feb;73(2):402-8. (PMID: 13394628)
Diabetes Care. 2012 Jul;35(7):1446-54. (PMID: 22584132)
Diabetes Metab Syndr Obes. 2012;5:419-24. (PMID: 23269874)
Clin Chem. 1993 May;39(5):746-56. (PMID: 8485865)
Pancreas. 1995 May;10(4):325-30. (PMID: 7540759)
Dig Dis Sci. 2007 Jan;52(1):1-17. (PMID: 17205399)
Clin Chem. 1984 Feb;30(2):343-4. (PMID: 6420090)
Gastroenterology. 2011 Jul;141(1):150-6. (PMID: 21334333)
J Clin Chem Clin Biochem. 1985 Jul;23(7):387-92. (PMID: 2413160)
Diabetes Care. 2010 Dec;33(12):2580-5. (PMID: 20833867)
Diabetes. 2005 Nov;54(11):3190-7. (PMID: 16249444)
Diabetes Care. 2009 May;32(5):834-8. (PMID: 19208917)
Clin Chem. 1972 Dec;18(12):1493-7. (PMID: 4639859)
Dig Dis Sci. 2003 Sep;48(9):1688-92. (PMID: 14560984)
Arch Pathol. 1961 Jan;71:44-59. (PMID: 13759774)
J Assoc Physicians India. 2008 Dec;56:987-8. (PMID: 19322980)
Am J Clin Pathol. 1991 Nov;96(5):610-4. (PMID: 1719798)
Am Heart J. 2013 Nov;166(5):823-30.e5. (PMID: 24176437)
Endocr Pract. 2012 Jul-Aug;18(4):472-7. (PMID: 22440997)
سلسلة جزيئية: ClinicalTrials.gov NCT01179048
المشرفين على المادة: 0 (Biomarkers)
0 (Hypoglycemic Agents)
839I73S42A (Liraglutide)
89750-14-1 (Glucagon-Like Peptide 1)
EC 3.1.1.3 (Lipase)
EC 3.2.1.- (Amylases)
تواريخ الأحداث: Date Created: 20141003 Date Completed: 20150622 Latest Revision: 20211021
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC4206347
DOI: 10.1097/MPA.0000000000000229
PMID: 25275271
قاعدة البيانات: MEDLINE
الوصف
تدمد:1536-4828
DOI:10.1097/MPA.0000000000000229